Synergy Pharmaceuticals Inc (SGYP) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 5.9% during the 3rd quarter, according to the company in …

Synergy Pharmaceuticals logoVanguard Group Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 5.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,025,593 shares of the biopharmaceutical company’s stock after purchasing an additional 1,224,873 shares during the quarter. Vanguard Group Inc. owned about 8.88% of Synergy Pharmaceuticals worth $37,444,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in Synergy Pharmaceuticals by 272.9% during the second quarter. Bank of America Corp DE now owns 243,363 shares of the biopharmaceutical company’s stock valued at $423,000 after buying an additional 384,085 shares during the period. Chicago Equity Partners LLC lifted its holdings in Synergy Pharmaceuticals by 153.5% in the third quarter. Chicago Equity Partners LLC now owns 472,535 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 286,135 shares during the period. Nexthera Capital LP bought a new position in shares of Synergy Pharmaceuticals during the third quarter valued at approximately $1,269,000. Hikari Power Ltd increased its stake in shares of Synergy Pharmaceuticals by 8.7% during the third quarter. Hikari Power Ltd now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $4,250,000 after purchasing an additional 200,000 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Synergy Pharmaceuticals by 2.2% during the second quarter. BlackRock Inc. now owns 21,732,054 shares of the biopharmaceutical company’s stock valued at $37,815,000 after purchasing an additional 464,195 shares in the last quarter. 37.22% of the stock is currently owned by hedge funds and other institutional investors.

SGYP has been the subject of a number of analyst reports. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, October 26th. Canaccord Genuity downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $5.33.

Shares of SGYP traded down $0.01 on Tuesday, hitting $0.28. 678,439 shares of the stock traded hands, compared to its average volume of 14,718,365. The company has a market capitalization of $68.93 million, a P/E ratio of -0.28 and a beta of 4.94. Synergy Pharmaceuticals Inc has a one year low of $0.07 and a one year high of $2.26.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.fairfieldcurrent.com/news/2019/02/12/synergy-pharmaceuticals-inc-sgyp-shares-bought-by-vanguard-group-inc.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Featured Story: SEC Filing

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Increases Holdings in Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

BlackRock Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 2.6% in the 3rd quarter, according to its most recent Form 13F …

Synergy Pharmaceuticals logoBlackRock Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 2.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,300,724 shares of the biopharmaceutical company’s stock after acquiring an additional 568,670 shares during the quarter. BlackRock Inc. owned 8.99% of Synergy Pharmaceuticals worth $37,910,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co. NY raised its stake in shares of Synergy Pharmaceuticals by 81.7% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 87,170 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 39,189 shares during the period. Bank of America Corp DE grew its holdings in Synergy Pharmaceuticals by 272.9% in the 2nd quarter. Bank of America Corp DE now owns 243,363 shares of the biopharmaceutical company’s stock valued at $423,000 after buying an additional 384,085 shares in the last quarter. Chicago Equity Partners LLC grew its holdings in Synergy Pharmaceuticals by 153.5% in the 3rd quarter. Chicago Equity Partners LLC now owns 472,535 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 286,135 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Synergy Pharmaceuticals by 7.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,312,030 shares of the biopharmaceutical company’s stock valued at $2,283,000 after buying an additional 88,386 shares in the last quarter. Finally, Hikari Power Ltd grew its holdings in Synergy Pharmaceuticals by 8.7% in the 3rd quarter. Hikari Power Ltd now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $4,250,000 after buying an additional 200,000 shares in the last quarter. Hedge funds and other institutional investors own 38.60% of the company’s stock.

Shares of NASDAQ SGYP opened at $0.33 on Thursday. The stock has a market cap of $74.39 million, a PE ratio of -0.32 and a beta of 3.02. Synergy Pharmaceuticals Inc has a fifty-two week low of $0.07 and a fifty-two week high of $2.80.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $11.11 million during the quarter, compared to the consensus estimate of $15.65 million.

A number of equities analysts have recently weighed in on the company. Canaccord Genuity cut Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Zacks Investment Research cut Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, BTIG Research cut Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. Synergy Pharmaceuticals has a consensus rating of “Hold” and an average price target of $6.50.

ILLEGAL ACTIVITY NOTICE: “BlackRock Inc. Increases Holdings in Synergy Pharmaceuticals Inc (NASDAQ:SGYP)” was first reported by Fairfield Current and is the property of of Fairfield Current. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.fairfieldcurrent.com/news/2019/01/24/blackrock-inc-has-37-91-million-stake-in-synergy-pharmaceuticals-inc-sgyp.html.

Synergy Pharmaceuticals Profile

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Featured Story: Short Selling

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Has $37.91 Million Stake in Synergy Pharmaceuticals Inc (SGYP)

BlackRock Inc. grew its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 2.6% during the 3rd quarter, according to the company in its …

Synergy Pharmaceuticals logoBlackRock Inc. grew its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,300,724 shares of the biopharmaceutical company’s stock after acquiring an additional 568,670 shares during the period. BlackRock Inc. owned about 8.99% of Synergy Pharmaceuticals worth $37,910,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Chicago Equity Partners LLC boosted its holdings in shares of Synergy Pharmaceuticals by 153.5% in the third quarter. Chicago Equity Partners LLC now owns 472,535 shares of the biopharmaceutical company’s stock valued at $803,000 after acquiring an additional 286,135 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its holdings in Synergy Pharmaceuticals by 81.7% during the second quarter. Metropolitan Life Insurance Co. NY now owns 87,170 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 39,189 shares in the last quarter. Bank of America Corp DE boosted its holdings in Synergy Pharmaceuticals by 272.9% during the second quarter. Bank of America Corp DE now owns 243,363 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 384,085 shares in the last quarter. Hikari Power Ltd boosted its holdings in Synergy Pharmaceuticals by 8.7% during the third quarter. Hikari Power Ltd now owns 2,500,000 shares of the biopharmaceutical company’s stock worth $4,250,000 after buying an additional 200,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Synergy Pharmaceuticals by 7.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 1,312,030 shares of the biopharmaceutical company’s stock worth $2,283,000 after buying an additional 88,386 shares in the last quarter. 38.60% of the stock is currently owned by institutional investors and hedge funds.

SGYP stock opened at $0.24 on Thursday. The stock has a market cap of $50.30 million, a P/E ratio of -0.23 and a beta of 3.02. Synergy Pharmaceuticals Inc has a 52 week low of $0.07 and a 52 week high of $2.80.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million. As a group, analysts forecast that Synergy Pharmaceuticals Inc will post -0.54 EPS for the current year.

A number of research firms recently commented on SGYP. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. Canaccord Genuity downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Finally, Zacks Investment Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $6.50.

TRADEMARK VIOLATION NOTICE: “BlackRock Inc. Has $37.91 Million Stake in Synergy Pharmaceuticals Inc (SGYP)” was reported by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/01/17/blackrock-inc-has-37-91-million-stake-in-synergy-pharmaceuticals-inc-sgyp.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Read More: How is the LIBOR rate calculated?

Want to see what other hedge funds are holding SGYP?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synergy Pharmaceuticals Inc (NASDAQ:SGYP).

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Have an attention on: Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), Laredo Petroleum, Inc …

Laredo Petroleum, Inc. (NYSE:LPI) closed at $3.04 by scoring -8.16%. The price/earnings to growth ratio (PEG ratio) is a stock’s price-to-earnings (P/E) …

On Tuesday, Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) reached at $0.07 price level during last trade its distance from 20 days simple moving average is -74.01%, and its distance from 50 days simple moving average is -87.79% while it has a distance of -95.22% from the 200 days simple moving average. The company’s distance from 52-week high price is -97.49% and current price is above +-6.40% from 52-week low price. Past 5 years growth of SGYP observed at N/A, and for the next five years the analysts that follow this company are expecting its growth at -9.30%. The average true range (ATR) is a measure of volatility introduced by Welles Wilder in his book, “New Concepts in Technical Trading Systems.” The true range indicator is the greatest of the following: current high less the current low, the absolute value of the current high less the previous close and the absolute value of the current low less the previous close. The average true range is a moving average, generally 14 days, of the true ranges. The company has Relative Strength Index (RSI 14) of 20.12 along with Average True Range (ATR 14) of 0.04. Its weekly and monthly volatility is 19.96%, 20.47% respectively.

Laredo Petroleum, Inc. (NYSE:LPI) closed at $3.04 by scoring -8.16%. The price/earnings to growth ratio (PEG ratio) is a stock’s price-to-earnings (P/E) ratio divided by the growth rate of its earnings for a specified time period. The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Currently has a PEG ratio of 0.03 where as its P/E ratio is 1.24. The overall volume in the last trading session was 3,318,658 shares while oil prices rose more than 3 per cent as bulls charged ahead in the wake of the Iran decision.

LPI’s price to sales ratio for trailing twelve months is 0.67 and price to book ratio for most recent quarter is 0.69, whereas price to cash per share for the most recent quarter is 15.11. The Company’s price to free cash flow for trailing twelve months is 1.48. Its quick ratio for most recent quarter is N/A. Analysts mean recommendation for the stock is 2.70. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Further, 0.40% shares of Omeros Corporation (NASDAQ:OMER) are owned by insiders with -30.71% six-month change in the insider ownership. The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. The stock closed at $10.72 by scoring -1.38%. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 2.70 as current ratio and on the opponent side the debt to equity ratio was N/A and long-term debt to equity ratio also remained N/A. The stock showed monthly performance of -23.15%. Likewise, the performance for the quarter was recorded as -59.49% and for the year was -46.51%.

Growth in earnings per share is everything. The expected future growth in earnings per share (“EPS”) is an incredibly important factor .in identifying an under-valued stock. The impact of earnings growth is exponential. Over the long run, the price of a stock will generally go up in lock step with its earnings (assuming the P/E ratio is constant). Therefore stocks with higher earnings growth should offer the highest capital gains. And doubling the growth more than doubles the capital gain, due to the compounding effect.

If we consider EPS growth of the company, then the company indicated the following observations:

The company showed -2.48 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -44.83%.

Omeros Corporation (NASDAQ:OMER) exchanged hands 751,833 shares versus average trading capacity of 948.61K shares, while its relative trading volume is 0.79. OMER’s total market worth is $529.35M. The Company has a Return on Assets of -123.70%. The company currently has a Return on Equity of 270.20% and Return on Investment of -53.70%.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. An example of the first is a treasury bill: the price does not go up or down a lot, so it has a low beta. An example of the second is gold. The price of gold does go up and down a lot, but not in the same direction or at the same time as the market.

A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. An example is a stock in a big technology company. Negative betas are possible for investments that tend to go down when the market goes up, and vice versa. There are few fundamental investments with comprising and noteworthy negative betas, but some derivatives like put options can have large negative betas.

Why Traders should have a look on beta and why it is important

Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an predictable return higher than the risk-free rate of interest.

Why higher-beta is riskier than lower-beta

Higher-beta stocks tend to be more volatile and therefore riskier, but provide the potential for higher returns. Lower-beta stocks pose less risk but generally offer lower returns. Some have challenged this idea, claiming that the data show little relation between beta and potential reward, or even that lower-beta stocks are both less risky and more profitable (contradicting CAPM). In the same way a stock’s beta shows its relation to market shifts, it is also an indicator for required returns on investment (ROI).

Now have a glance on “Beta value” of these three stocks

SGYP’s Beta value is 2.75.

LPI’s Beta value is 1.59.

OMER’s Beta value is 3.68.

DISCLAIMER: This article is published by journalfinance.net. The content included in this article is just for informational purposes only. Journalfinance.net takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable. Neither Journalfinance.net nor any of Journalfinance.net partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article. Read more.

Related Posts:

  • No Related Posts

Top Movers Performance Overview-3D Systems Corporation (DDD), Synergy Pharmaceuticals, Inc …

The shares of 3D Systems Corporation (NYSE:DDD) and Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) were among the active stocks of the last …

The shares of 3D Systems Corporation (NYSE:DDD) and Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) were among the active stocks of the last trading sessions. 3D Systems Corporation (NYSE:DDD) soared to 7.8% closing at the price of $14.09 whereas the shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) soared 7.59% with the increase of 0.12 points closing at the price of $1.7. 3D Systems Corporation has currently increase 56.9% in its stock over the period of 6-months while its rival Synergy Pharmaceuticals, Inc. subtracted -15% in the previous 6-months.

Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.



Returns and Profitability

Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.

The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of 3D Systems Corporation (NYSE:DDD) is -9.9% while the ROI of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) is -201.1%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, DDD’s EBITDA Margin is 152.48 whereas SGYP’s is -1.92.

Both the profitability ratios suggest that 3D Systems Corporation (NYSE:DDD) is more suitable investment in terms of profitability and return.



EPS & Surprise Factor

3D Systems Corporation (NYSE:DDD) reported $-0.03/share EPS for the previous quarter where analysts were predicting an EPS to be $0.01/share Thus lagging the analyst Estimates with a Surprise Factor of -400 Percent. While, Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) reported EPS of $-0.15/share in the last quarter. The analysts projected EPS of $-0.16/share depicting a Surprise of 6.3 Percent.

Taking a look at Earnings per Share, Synergy Pharmaceuticals, Inc. tends to be beating the analyst estimates more than 3D Systems Corporation. so SGYP is more profitable than DDD.



Technical Analysis of 3D Systems Corporation & Synergy Pharmaceuticals, Inc.

Moving average convergence divergence (MACD) shows that 3D Systems Corporation (NYSE:DDD) is on a PRICE RELATIVITY trend While Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the 3D Systems Corporation was in BULLISH territory and Synergy Pharmaceuticals, Inc. was in BULLISH territory.

DDD’s current statistics gauge that the stock candle is BULLISH with MEDIUM volatility. While SGYP’s candle is BULLISH with LOW.



EPS Growth Rate: DDD’s 10% versus SGYP’s 0%

Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of 3D Systems Corporation (NYSE:DDD) is predicted at 10% while Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) stands at 0%. These numbers suggest that DDD is more suitable investment in terms of EPS growth rate.



Financial Risk and Liquidity Concerns

The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of DDD stands at 2 while SGYP is at 3.1 whereas the debt ratio of the prior is 0.01 while the debt ratio of the later is 0.

The values of the both ratios suggest that one is more liquid and other investment is more risk free.



Analyst Recommendations

While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 3.3 for DDD and 2.3 for SGYP which means DDD has Sell rating whereas SGYP has Hold rating.

Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for DDD is $9.88 which is -42.61% of its current price while SGYP has price target of 7.08 which is 75.99% of its current price.



Valuation Ratios

Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.

DDD currently has price to earning P/E ratio of 0 whereas SGYP has 0 while the forward P/E ratio for the prior stands at 62.35 and for the later it depicts the value of 0.

The price to Book P/B for DDD is 2.58, Price to Sale is at 2.43 and for SGYP these ratios stand at 0 and 16.58.

Related Posts: